Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
Phase 1 trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with nivolumab for treatment of recurrent glioblastoma BOSTON , June 28, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing
View HTML
Toggle Summary Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
BOSTON , June 18, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced the U.S. Food and Drug Administration ( FDA ) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional information in
View HTML
Toggle Summary Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
- Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers - Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20mg veledimex cohort who received Controlled IL-12 as a single agent - Over expression of immune checkpoint biomarkers demonstrated
View HTML
Toggle Summary Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
-       Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers -       IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients with recurrent glioblastoma -       Results further support development of
View HTML
Toggle Summary Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
-Expanding Controlled IL-12 platform to explore additional tumor types -Cash runway extended to 2Q 2019 with changes to Controlled IL-12 development plans -ASCO poster to detail IL-12 data in breast cancer, glioblastoma, highlight potential for combination with checkpoint inhibitors
View HTML
Toggle Summary Ziopharm Oncology to Announce First Quarter 2018 Financial Results, Host Conference Call May 10
BOSTON , May 02, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, May 10 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended
View HTML
Toggle Summary Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Company to host conference call today at 4:30 p.m. ET
View HTML
Toggle Summary Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1
BOSTON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, March 1, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and
View HTML
Toggle Summary Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond
Human CAR+ T cells with membrane-bound IL-15 manufactured in less than two days exhibited anti-tumor activity and persistence in pre-clinical studies
View HTML
Toggle Summary Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance
BOSTON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no developments at the Company that would be the cause of the recent volatility and decline in
View HTML